Platelet factor 4: a key effector molecule of plasmacytoid dendritic cells in systemic sclerosis

Author: Senior Product Manager of UA Views：11

This article systematically elucidates the core role of platelet factor 4 (PF4/CXCL4) as the major secretory protein of plasmacytoid dendritic cells in the pathogenesis of systemic sclerosis, analyzing the association between PF4 levels and clinical complications such as skin fibrosis, pulmonary fibrosis, and pulmonary hypertension. It explores the molecular mechanisms by which PF4 induces endothelial cell activation through downregulation of FLI1 expression and enhancement of TLR responses.

Recent Advances
Product Information

Recent Advances

Platelet Factor 4: A Key Effector Molecule of Plasmacytoid Dendritic Cells in Systemic Sclerosis

Summary: This article focuses on the molecular characteristics and biological functions of Platelet Factor 4 (PF4/CXCL4), systematically elaborating its central role in the pathogenesis of systemic sclerosis as the main secretory protein of plasmacytoid dendritic cells. It analyzes the association between PF4 levels and clinical complications such as skin fibrosis, pulmonary fibrosis, and pulmonary hypertension, and explores the molecular mechanisms by which PF4 induces endothelial cell activation by downregulating FLI1 expression and enhancing TLR responses.

1. Disease Characteristics of Systemic Sclerosis and the Need for Biomarker Research

Systemic sclerosis, also known as scleroderma, is a complex heterogeneous fibrotic autoimmune disease with an unknown pathogenesis. Identifying biomarkers for the existence and progression of clinical complications in systemic sclerosis has potential applications in assessing disease activity. Plasmacytoid dendritic cells are the primary source of type I interferons. Although studies have shown that serum samples obtained from systemic sclerosis patients exhibit type I interferon-inducing activity, the role of plasmacytoid dendritic cells in systemic sclerosis has not been fully explored. Therefore, researchers aimed to determine the possible role of plasmacytoid dendritic cells in the pathogenesis of systemic sclerosis related to clinical phenotypes. This research background raises a key question: Through which secretory factors do plasmacytoid dendritic cells participate in the pathological process of systemic sclerosis?

2. Molecular Characteristics and Expression Distribution of PF4

CXCL4, also known as Platelet Factor 4, is a member of the C-X-C chemokine family and was the first chemokine to be identified. The human PF4 gene encodes a mature protein of approximately 7.8 kDa, consisting of 70 amino acids. CXCL4 is primarily localized in the α-granules of platelets, with about 20 micrograms of PF4 per 1×10^9 platelet cells, indicating an extremely high concentration. In plasma, the concentration of PF4 is approximately 2 to 10 ng/mL. This distribution feature—highly enriched in platelets but maintained at low levels in plasma—allows PF4 to be rapidly released and exert local regulatory effects upon platelet activation. Recent studies have found that PF4 is not only a hallmark secretory product of platelets but also the main protein secreted by plasmacytoid dendritic cells under specific pathological conditions.

3. Elevated Expression of PF4 in Systemic Sclerosis and Clinical Associations

Global proteomic analysis and validation have shown that CXCL4 is the main protein secreted by plasmacytoid dendritic cells in systemic sclerosis, both in circulation and in the skin. The average CXCL4 level in systemic sclerosis patients was 25,624±2,652 pg/mL, significantly higher than that in the control group (92.5±77.9 pg/mL), as well as in patients with systemic lupus erythematosus (1,346±1,011 pg/mL), ankylosing spondylitis (1,368±1,162 pg/mL), or liver fibrosis (1,668±1,263 pg/mL). This notable concentration difference indicates that PF4 exhibits disease-specific elevation in systemic sclerosis.

CXCL4 levels are associated with skin and pulmonary fibrosis as well as pulmonary hypertension. Among chemokines, only CXCL4 can predict the risk and progression of systemic sclerosis. This finding establishes PF4's unique position as a biomarker for systemic sclerosis, with predictive value superior to other chemokines. Elevated CXCL4 levels in systemic sclerosis patients are correlated with the presence and progression of complications such as pulmonary fibrosis and pulmonary hypertension, suggesting that PF4 could serve as a potential indicator for assessing disease activity and complication risks.

4. Molecular Mechanisms of PF4-Induced Endothelial Cell Activation and Inflammatory Responses

In vitro experiments, CXCL4 downregulated the expression of the transcription factor FLI1, induced markers of endothelial cell activation, and enhanced Toll-like receptor responses. FLI1 is a key transcription factor for maintaining endothelial cell homeostasis and inhibiting fibrosis, and its downregulation is closely related to endothelial cell dysfunction and vascular pathology in systemic sclerosis. By suppressing FLI1 expression, CXCL4 promotes the transition of endothelial cells to a pro-inflammatory and pro-fibrotic phenotype.

In vivo experiments, CXCL4 induced the influx of inflammatory cells and changes in skin transcriptomes, similar to those observed in systemic sclerosis. These experimental findings suggest that PF4 is not only a marker of systemic sclerosis but also a functional mediator driving the disease's pathological progression. By inducing endothelial cell activation and enhancing Toll-like receptor responses, PF4 amplifies inflammatory cascades, thereby driving fibrosis in the skin and lungs.

5. Pleiotropic Biological Functions of PF4

CXCL4 exhibits pleiotropic biological functions. It is considered a potent anti-angiogenic chemokine, capable of inhibiting endothelial cell proliferation and migration, thereby suppressing angiogenesis. The vascular quiescence activity of CXCL4 involves multiple mechanisms, including interference with angiogenic growth factors such as bFGF-2 and VEGF165, activation of the CXCR3B receptor (a splice variant of CXCR3), interactions with integrins, and disruption of cell cycle progression. In systemic sclerosis, PF4's anti-angiogenic activity may contribute to vascular pathology, a core pathological feature of the disease. Through various mechanisms, PF4 regulates endothelial cell function, playing a pivotal role in vascular homeostasis imbalance and fibrosis progression.

6. Conclusion

In PF4-related basic research and drug development, high-quality recombinant PF4 protein is a core tool for elucidating its pro-fibrotic and pro-inflammatory mechanisms. To meet this research need, UniLove provides CXCL4/PF4 Protein, Human. This product is suitable for studying PF4's pro-fibrotic mechanisms in systemic sclerosis, analyzing PF4's interactions with endothelial and immune cells, and evaluating PF4-targeted therapeutic strategies.

As the first chemokine to be identified, Platelet Factor 4 has evolved into an important target for research on the pathogenesis and clinical assessment of systemic sclerosis, owing to its high enrichment in platelets, its unique role as the main secretory protein of plasmacytoid dendritic cells in systemic sclerosis, and its significant association with complications such as pulmonary fibrosis and pulmonary hypertension. Its molecular mechanisms—inducing endothelial cell activation by downregulating FLI1 expression and enhancing Toll-like receptor responses—provide new perspectives for understanding vascular pathology and fibrosis progression in systemic sclerosis. CXCL4/PF4 Protein, Human offers reliable tool support for PF4-related mechanism research and targeted strategy development, continuing to drive in-depth exploration in the field of systemic sclerosis treatment.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next